Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients
By using the highly sensitive ddPCR approach, we detected minor clones with on-target resistant mutations in both treatment-naive and relapse biopsies from ALK-positive NSCLC patients. The predictive value of these mutations as the potential resistance-causing mechanism was limited to relapses occurring at the same tumor location as the pre-treatment sample.
Authors
- Jessica Bucher
- Anthonie J. van der Wekken (ORCID: https://orcid.org/0000-0001-7175-0026)
- Anke van den Berg (ORCID: https://orcid.org/0000-0002-8894-2638)
- Klaas Kok (ORCID: https://orcid.org/0000-0001-8655-3439)
- Frank J.G. Scherpen
- Weiting Li (ORCID: https://orcid.org/0000-0003-1789-1498)
- Fenneke Zwierenga (ORCID: https://orcid.org/0000-0001-8993-0105)
- Harry J.M. Groen (ORCID: https://orcid.org/0000-0002-2978-5265)
- T. Jeroen N. Hiltermann (ORCID: https://orcid.org/0000-0002-0665-2160)
- Katarina D. Andini (ORCID: https://orcid.org/0000-0003-1541-0128)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-25
- DOI
- https://doi.org/10.3390/cancers17071090
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- China Scholarship Council